BRCA1 promoter methylation predicts PARPi response in ovarian cancer: insights from the KOMET study
Abstract Objectives PARP inhibitors (PARPi) have become the new standard maintenance treatment for patients with advanced homologous recombination deficiency (HRD) ovarian cancer; they are also used upon platinum-sensitive relapse. HRD in ovarian cancer is primarily assessed through BRCA genes mutat...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Clinical Epigenetics |
| Online Access: | https://doi.org/10.1186/s13148-025-01917-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|